Intramuscular and subcutaneous levothyroxine : success in treating refractory hypothyroidism
Chaudhury, Nadia Crasto, Winston Saravanan, Ponnusamy Patel, Vinod
Chaudhury, Nadia
Crasto, Winston
Saravanan, Ponnusamy
Patel, Vinod
Affiliation
George Eliot Hospital NHS Trust, Nuneaton; University of Warwick, Coventry
Other Contributors
Publication date
2025-03-31
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Refractory hypothyroidism often poses a clinical problem, as treatment regimens are difficult to individualise to the patient and the feasibility of its delivery is difficult to organise within a healthcare system. We present a patient who became intolerant of intramuscular (IM) levothyroxine (LT4) after 18 years of treatment; thus, subcutaneous (SC) LT4 was initiated.
Case presentation: A 13-year-old female with newly diagnosed hypothyroidism remained hypothyroid despite escalating doses of oral LT4 and LT3. Thyroxine malabsorption was further suggested by nasogastric administration of LT4, whereby high-dose thyroxine administration resulted in only a 2.8 pmol/L increase in free T4 level (normal >5.14 pmol/L). She eventually achieved long-term euthyroid status at the age of 18 with fortnightly IM LT4 alongside oral LT4 and LT3. This was maintained for 18 years. Unfortunately, scar tissue developed around injection sites, resulting in increased pain and difficulty in administration. SC LT4 was trialled with success, and she has remained euthyroid for the last 6 years with self-administration and minimal side effects.
Conclusion: Refractory hypothyroidism often presents a challenge for clinicians, both for diagnosis and management. We discuss a patient with the longest follow-up to date within the published literature for both IM and SC LT4 for patient-administered treatment of refractory hypothyroidism and review the literature on alternative formulations available.
Citation
Chaudhury N, Crasto W, Saravanan P, Patel V. Intramuscular and subcutaneous levothyroxine: success in treating refractory hypothyroidism. Eur Thyroid J. 2025 Apr 10;14(2):e250012. doi: 10.1530/ETJ-25-0012.
Type
Article
Description
Copyright: © the author(s) 2025
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes .
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.